Thus, the combination therapy using AAV1.hSERCA2a gene therapy with a STAT3 inhibitor could represent a new promising therapeutic option to inhibit PAH and to restore BMPR2 expression in pulmonary vascular cells. Here, BMPR2 is linked to pulmonary arterial hypertension.